Live feed07:05:00·225dPRReleasevia QuantisnowPureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy VolunteersByQuantisnow·Wall Street's wire, on your screen.PRTC· PureTech Health plcHealth Care